Axsome Therapeutics (AXSM) Short term Debt (2016 - 2026)

Axsome Therapeutics' Short term Debt history runs 10 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• In Q1 2026, Short term Debt rose 29.62% year-over-year to $11.2 million; the TTM figure through Mar 2026 stood at $11.2 million (up 29.62% YoY), while the FY2025 annual figure was $10.0 million, changed N/A from the prior year.
• Short term Debt came in at $11.2 million for Q1 2026 at Axsome Therapeutics, up from $10.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $70.0 million in Q2 2025 to a low of $5.9 million in Q4 2022.
• A 5-year average of $11.7 million and a median of $7.0 million in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt fell 4.69% in 2023 and surged 894.32% in 2025, its largest moves.
• Axsome Therapeutics' Short term Debt stood at $5.9 million in 2022, then rose by 8.59% to $6.4 million in 2023, then increased by 26.91% to $8.1 million in 2024, then grew by 23.13% to $10.0 million in 2025, then grew by 11.37% to $11.2 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $11.2 million, $10.0 million, and $9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison